NI201900109A - Parche que contiene rupatadina - Google Patents

Parche que contiene rupatadina

Info

Publication number
NI201900109A
NI201900109A NI201900109A NI201900109A NI201900109A NI 201900109 A NI201900109 A NI 201900109A NI 201900109 A NI201900109 A NI 201900109A NI 201900109 A NI201900109 A NI 201900109A NI 201900109 A NI201900109 A NI 201900109A
Authority
NI
Nicaragua
Prior art keywords
rupatadine
adhesive
patch containing
acrylic adhesive
adhesive base
Prior art date
Application number
NI201900109A
Other languages
English (en)
Inventor
Kawakami Satoshi
Sogabe Manabu
Original Assignee
J Uriach Y Compania S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by J Uriach Y Compania S A filed Critical J Uriach Y Compania S A
Publication of NI201900109A publication Critical patent/NI201900109A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se proporciona un parche externo que contiene rupatadina como antihistamina de segunda generación, tiene excelentes propiedades físicas de esparadrapo, buena adhesión cuando se aplica a la piel, y buena absorción transdérmica de rupatadina como principio activo. El parche externo que contiene rupatadina usa un adhesivo acrílico como base adhesiva. Específicamente, el parche externo que contiene rupatadina usa un adhesivo acrílico como base adhesiva y además contiene un ácido orgánico que tiene de 2 a 7 átomos de carbono como agente de solubilidad, un éster de ácido graso como agente de reblandecimiento y/o un tensioactivo.
NI201900109A 2017-04-19 2019-10-18 Parche que contiene rupatadina NI201900109A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2017082559 2017-04-19

Publications (1)

Publication Number Publication Date
NI201900109A true NI201900109A (es) 2020-01-07

Family

ID=63856668

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201900109A NI201900109A (es) 2017-04-19 2019-10-18 Parche que contiene rupatadina

Country Status (15)

Country Link
US (1) US11179346B2 (es)
EP (1) EP3612182B1 (es)
JP (1) JP7228527B2 (es)
KR (1) KR102586423B1 (es)
CN (1) CN110740730B (es)
BR (1) BR112019021807A2 (es)
CA (1) CA3059682A1 (es)
CR (1) CR20190527A (es)
DO (1) DOP2019000270A (es)
ES (1) ES2971461T3 (es)
FI (1) FI3612182T3 (es)
NI (1) NI201900109A (es)
PL (1) PL3612182T3 (es)
TW (1) TWI825013B (es)
WO (1) WO2018194183A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102577838B1 (ko) * 2020-10-29 2023-09-12 히사미쓰 세이야꾸 가부시키가이샤 로피니롤 함유 첩부제 및 로피니롤의 피부 투과성 향상 방법
CN112494429B (zh) * 2020-12-29 2022-07-26 北京华氏开元医药科技有限公司 一种富马酸卢帕他定纳米乳液及其制备方法与应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2042421B1 (es) 1992-05-22 1994-08-01 Uriach & Cia Sa J Procedimiento para la obtencion de la 8-cloro-11-*1-*(5-metil-3-piridil)metil*-4-piperidiliden*-6,11-dihidro-5h-benzo*5,6*ciclohepta*1,2-b*piridina.
EP1335689B1 (en) * 2000-10-23 2010-03-17 Euro-Celtique S.A. Loratadine transdermal administration system and use thereof
DE10060852A1 (de) * 2000-12-06 2002-06-20 Hexal Ag Absorptionsmittel und Kanalbildner enthaltende wirkstoffundurchlässige Deckschicht oder abziehbare Schutzschicht eines transdermalen therapeutischen Systems
CN100411692C (zh) * 2004-01-13 2008-08-20 北京康倍得医药技术开发有限公司 丙烯酸基粘合剂组合物及其药物组合物和透皮治疗系统
ES2437077T3 (es) 2005-07-08 2014-01-08 Senju Pharmaceutical Co., Ltd. Preparado oftálmico de absorción percutánea que comprende olopatadina
EP2008651A1 (en) 2007-06-26 2008-12-31 Drug Delivery Solutions Limited A bioerodible patch
CN101933914A (zh) 2009-06-29 2011-01-05 杭州赛利药物研究所有限公司 地氯雷他定贴剂及其制备方法
JP5837276B2 (ja) * 2009-09-30 2015-12-24 味の素株式会社 経口摂取用ゲル状組成物、及びその製造方法
EP2588472B1 (en) 2010-06-30 2014-04-09 J. Uriach y Compania S.A. RUPATADINE derivative AS AN ANTIHISTAMINIC AGENT
US11224619B2 (en) 2012-04-16 2022-01-18 Zemtsov Enterprises, Llc Formulations and methods for treatment of inflammatory skin diseases

Also Published As

Publication number Publication date
US11179346B2 (en) 2021-11-23
JP2020524657A (ja) 2020-08-20
JP7228527B2 (ja) 2023-02-24
CN110740730B (zh) 2024-01-09
ES2971461T3 (es) 2024-06-05
EP3612182A1 (en) 2020-02-26
TW201841638A (zh) 2018-12-01
RU2019136691A3 (es) 2021-07-13
KR102586423B1 (ko) 2023-10-11
EP3612182A4 (en) 2020-09-16
DOP2019000270A (es) 2019-12-30
WO2018194183A1 (en) 2018-10-25
PL3612182T3 (pl) 2024-05-13
CN110740730A (zh) 2020-01-31
BR112019021807A2 (pt) 2020-05-05
CR20190527A (es) 2020-03-17
CA3059682A1 (en) 2018-10-25
TWI825013B (zh) 2023-12-11
KR20200006065A (ko) 2020-01-17
RU2019136691A (ru) 2021-05-17
US20200121612A1 (en) 2020-04-23
EP3612182B1 (en) 2024-01-10
FI3612182T3 (fi) 2024-02-19

Similar Documents

Publication Publication Date Title
AR128490A2 (es) Compuesto derivado de carboxamida para el control de endoparásitos
BR112016006215A2 (pt) composição de polímero termoplástico
CR10748A (es) Compuesto de indol
CL2015002710A1 (es) Composiciones de arni contra el componente c5 del complemento y métodos para su uso.
MX2017000102A (es) Calzado que tiene estructuras augeticas con propiedades controladas.
PE20150200A1 (es) Formulacion de anticuerpos
DOP2010000267A (es) Compuesto heterociclico
UY35300A (es) Formulación de combinación de dos compuestos antivirales
NI201900109A (es) Parche que contiene rupatadina
PE20141200A1 (es) Formulacion de una capsula que comprende montelukast y levocetirizina
CR20120345A (es) Derivados de 3-hidroxi-5-arilisotiazol novedosos
PE20150024A1 (es) Compuestos que inhiben la actividad de catecol o-metiltransferasa
BR112018006103A2 (pt) aplicador de precisão
CR20130024A (es) Compuestos heterocíclicos fusionados
UY32004A (es) Derivados de carbamatos de alquiltiazoles, su preparación y su aplicación en terapéutica
DOP2016000013A (es) Repelente de insectos
CO6351710A2 (es) Composicion topica para el tratamiento de queratosis actinica
CO2019012125A2 (es) Inhibidores ip6k
BR112014011066A8 (pt) artigo absorvente com elemento de estabilização
PE20151669A1 (es) Compuestos de azetidiniloxifenilpirrolidina
AR075537A1 (es) Formulacion ectoparasiticida con fragancia mejorada
CL2015002721A1 (es) Formulaciones oftálmicas
BR112016006201A2 (pt) composição de polímero termoplástico
AR090430A1 (es) Articulo absorbente
BR112013028531A2 (pt) composição inseticida líquida